Silva Matthew J, Brodt Michael D, Ko Mike, Abu-Amer Yousef
Department of Orthopaedic Surgery, Barnes-Jewish Hospital at Washington University, St Louis, Missouri 63110, USA.
J Bone Miner Res. 2005 Mar;20(3):419-27. doi: 10.1359/JBMR.041128. Epub 2004 Nov 29.
We used the SAMP6 osteoporotic mouse to examine the link between marrow osteogenic potential and in vivo cortical bone formation. SAMP6 marrow supported less in vitro osteogenesis than marrow from SAMR1 controls; SAMP6 mice had a corresponding deficit in endocortical mineralizing surface. This marrow/endocortical defect did not affect the periosteum, where SAMP6 mice had normal to enhanced bone formation.
With aging, there may be a reduction in the number or proliferative capacity of bone marrow osteoprogenitors that may contribute to age-related decreases in bone formation. To examine the link between the ability of the marrow to support osteogenesis and age-related changes in bone formation, we measured in vitro and in vivo indices of osteogenesis in a model of osteoporosis, the senescence-accelerated mouse SAMP6.
Femora and tibias from SAMP6 and SAMR1 (control) mice were harvested at 2, 4, 6, and 12 months of age (168 bones total). Bone marrow cells were cultured under osteogenic conditions and stained for alkaline phosphatase (ALP) and alizarin red. Dynamic indices of bone formation were assessed histologically from calcein labels.
ALP+ and alizarin red-positive areas were significantly less in cultures from SAMP6 bones versus SAMR1 (p < 0.05), indicating less osteogenic potential. For example, SAMP6 tibial cultures had 21% less ALP+ area and 36% less alizarin red-positive area than SAMR1. Marrow from tibias had 2-fold greater osteogenesis than femoral marrow (p < 0.001). SAMP6 mice had a deficit in endocortical mineralizing surface across all age groups (p < 0.05), but no deficit in mineral apposition rate. Last, despite the marrow and endocortical deficits, SAMP6 mice had normal or slightly increased periosteal bone formation, consistent with their larger bone size.
SAMP6 bone marrow supports less in vitro osteogenesis than SAMR1, consistent with a lower concentration of marrow osteoprogenitors in SAMP6. SAMP6 mice have less endocortical mineralizing surface than SAMR1 at all ages but no detectable deficit in mineral apposition rate, which suggests a reduction in osteoblast number but normal function. Periosteal bone formation is unimpaired in SAMP6 mice, indicating that the marrow/endocortical defect does not affect the periosteal surface.
我们使用SAMP6骨质疏松小鼠来研究骨髓成骨潜能与体内皮质骨形成之间的联系。与SAMR1对照小鼠的骨髓相比,SAMP6骨髓在体外支持的成骨作用较少;SAMP6小鼠在内皮质矿化表面存在相应的缺陷。这种骨髓/内皮质缺陷并未影响骨膜,SAMP6小鼠的骨膜处骨形成正常或增强。
随着年龄增长,骨髓骨祖细胞的数量或增殖能力可能会降低,这可能导致与年龄相关的骨形成减少。为了研究骨髓支持成骨的能力与骨形成的年龄相关变化之间的联系,我们在骨质疏松模型——衰老加速小鼠SAMP6中测量了体外和体内的成骨指标。
在2、4、6和12月龄时采集SAMP6和SAMR1(对照)小鼠的股骨和胫骨(共168块骨)。将骨髓细胞在成骨条件下培养,并用碱性磷酸酶(ALP)和茜素红染色。通过钙黄绿素标记组织学评估骨形成的动态指标。
与SAMR1相比,SAMP6骨培养物中的ALP +和茜素红阳性区域明显较少(p <0.05),表明成骨潜能较低。例如,SAMP6胫骨培养物的ALP +区域比SAMR1少21%,茜素红阳性区域少36%。胫骨骨髓的成骨作用比股骨骨髓大2倍(p <0.001)。SAMP6小鼠在所有年龄组的内皮质矿化表面均存在缺陷(p <0.05),但矿化沉积率无缺陷。最后,尽管存在骨髓和内皮质缺陷,但SAMP6小鼠的骨膜骨形成正常或略有增加,这与其较大的骨骼尺寸一致。
SAMP6骨髓在体外支持的成骨作用比SAMR1少,这与SAMP6中骨髓骨祖细胞浓度较低一致。SAMP6小鼠在所有年龄段的内皮质矿化表面均比SAMR1少,但矿化沉积率无明显缺陷,这表明成骨细胞数量减少但功能正常。SAMP6小鼠的骨膜骨形成未受影响,表明骨髓/内皮质缺陷不影响骨膜表面。